Literature DB >> 21239473

The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth.

Floriane Pez1, Frédéric Dayan, Jérome Durivault, Bastien Kaniewski, Géraldine Aimond, Gabrielle S Le Provost, Blandine Deux, Philippe Clézardin, Pascal Sommer, Jacques Pouysségur, Caroline Reynaud.   

Abstract

Adaptation to hypoxia is a driving force for tumor progression that leads to therapy resistance and poor clinical outcome. Hypoxic responses are mainly mediated by hypoxia-inducible transcription factor-1 (HIF-1). One critical HIF-1 target mediating tumor progression is lysyl oxidase (LOX), which catalyzes cross-linking of collagens and elastin in the extracellular matrix, thereby regulating tissue tensile strength. Paradoxically, LOX has been reported to be both upregulated and downregulated in cancer cells, especially in colorectal cancer. Thus, we hypothesized that LOX might regulate expression of HIF-1 to create a self-timing regulatory circuit. Using human colorectal carcinoma cell lines in which HIF-1 and LOX expression could be modulated, we showed that LOX induction enhanced HIF-1 expression, whereas LOX silencing reduced it. Mechanistic investigations revealed that LOX activated the PI3K (phosphoinositide 3-kinase)-Akt signaling pathway, thereby upregulating HIF-1α protein synthesis in a manner requiring LOX-mediated hydrogen peroxide production. Consistent with these results, cancer cell proliferation was stimulated by secreted and active LOX in an HIF-1α-dependent fashion. Furthermore, nude mice xenograft assays established that HIF-1 potentiated LOX action on tumor growth in vivo. Taken together, these findings provide compelling evidence that LOX and HIF-1 act in synergy to foster tumor formation, and they suggest that HIF-1/LOX mutual regulation is a pivotal mechanism in the adaptation of tumor cells to hypoxia. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239473     DOI: 10.1158/0008-5472.CAN-10-1516

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  LOX and ACSL5 as potential relapse markers for pancreatic cancer patients.

Authors:  Weidong Ma; Ting Li; Si Wu; Jian Li; Xiuchao Wang; Hui Li
Journal:  Cancer Biol Ther       Date:  2019-02-03       Impact factor: 4.742

Review 2.  Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.

Authors:  Biagio Ricciuti; Jennifer Foglietta; Rita Chiari; Amirhossein Sahebkar; Maciej Banach; Vanessa Bianconi; Matteo Pirro
Journal:  Med Oncol       Date:  2017-12-04       Impact factor: 3.064

3.  Lysyl oxidase may play a critical role in hypoxia-induced NSCLC cells invasion and migration.

Authors:  Ling Wei; Xian-Rang Song; Ju-Jie Sun; Xing-Wu Wang; Li Xie; Li-Yan Lv
Journal:  Cancer Biother Radiopharm       Date:  2012-11-09       Impact factor: 3.099

Review 4.  Transcriptional control of cancer metastasis.

Authors:  Brian Ell; Yibin Kang
Journal:  Trends Cell Biol       Date:  2013-07-06       Impact factor: 20.808

5.  Clioquinol inhibits dopamine-β-hydroxylase secretion and noradrenaline synthesis by affecting the redox status of ATOX1 and copper transport in human neuroblastoma SH-SY5Y cells.

Authors:  Masato Katsuyama; En Kimura; Masakazu Ibi; Kazumi Iwata; Misaki Matsumoto; Nozomi Asaoka; Chihiro Yabe-Nishimura
Journal:  Arch Toxicol       Date:  2020-10-09       Impact factor: 5.153

6.  HIF2α in the uterine stroma permits embryo invasion and luminal epithelium detachment.

Authors:  Leona Matsumoto; Yasushi Hirota; Tomoko Saito-Fujita; Norihiko Takeda; Tomoki Tanaka; Takehiro Hiraoka; Shun Akaeda; Hidetoshi Fujita; Ryoko Shimizu-Hirota; Shota Igaue; Mitsunori Matsuo; Hirofumi Haraguchi; Mayuko Saito-Kanatani; Tomoyuki Fujii; Yutaka Osuga
Journal:  J Clin Invest       Date:  2018-06-18       Impact factor: 14.808

7.  Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy.

Authors:  Christelle P El-Haibi; George W Bell; Jiangwen Zhang; Anthony Y Collmann; David Wood; Cally M Scherber; Eva Csizmadia; Odette Mariani; Cuihua Zhu; Antoine Campagne; Mehmet Toner; Sangeeta N Bhatia; Daniel Irimia; Anne Vincent-Salomon; Antoine E Karnoub
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-02       Impact factor: 11.205

8.  Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma.

Authors:  Xiao-Hong Wu; Su-Ping Chen; Jian-Ying Mao; Xue-Xian Ji; Hong-Tian Yao; Shui-Hong Zhou
Journal:  Oncol Lett       Date:  2012-09-26       Impact factor: 2.967

9.  Sildenafil alleviates bronchopulmonary dysplasia in neonatal rats by activating the hypoxia-inducible factor signaling pathway.

Authors:  Hyoung-Sook Park; Jong-Wan Park; Hye-Jin Kim; Chang Won Choi; Hyun-Ju Lee; Byung Il Kim; Yang-Sook Chun
Journal:  Am J Respir Cell Mol Biol       Date:  2012-10-11       Impact factor: 6.914

Review 10.  The role of estrogen receptor β in prostate cancer.

Authors:  Paraskevi Christoforou; Panagiotis F Christopoulos; Michael Koutsilieris
Journal:  Mol Med       Date:  2014-10-02       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.